Evidence map›Paper›PMID 42282892›Full record

Trial reportCancer communications (London, England)2026

Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.

Xuezhi Hao, Lin Wang, Yanrong Hao, Yanping Hu, Chun Chen, Bi Chen, Yunchao Huang, Aimin Zang, Yan Wang, Zhendong Chen and 19 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer communications (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Xuezhi HaoDepartment of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.
Lin WangDepartment of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.
Yanrong HaoDepartment of Medical Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
Yanping HuDepartment of Medical Oncology, Hubei Cancer Hospital, Wuhan, Hubei, P. R. China.
Chun ChenDepartment of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, P. R. China.
Bi ChenDepartment of Respiratory and Critical Care Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, P. R. China.
Yunchao HuangDepartment of Thoracic Surgery I, Yunnan Cancer Hospital, Kunming, Yunnan, P. R. China.
Aimin ZangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, Hebei, P. R. China.
Yan WangDepartment of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.
Zhendong ChenDepartment of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.
Wu ZhuangDepartment of Thoracic Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, P. R. China.
Jinsheng ShiDepartment of Oncology, Cangzhou People's Hospital, Cangzhou, Hebei, P. R. China.
Xiubao RenDepartment of Biotherapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, P. R. China.
Ligong NieDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, P. R. China.
Guohua YuDepartment of Medical Oncology, Weifang People's Hospital, Weifang, Shandong, P. R. China.
Feng LuoLung Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
Yimin MaoDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, P. R. China.
Xiang WangDepartment of Medical Oncology, Xuzhou Central Hospital, Xuzhou, Jiangsu, P. R. China.
Baolan LiDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, P. R. China.
Yuansong BaiDepartment of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, P. R. China.
Jianhua ShiDepartment of Medical Oncology, Linyi Cancer Hospital, Linyi, Shandong, P. R. China.
Hongyan NiGlobal Product Development, Shanghai Henlius Biotech, Inc., Shanghai, P. R. China.
Xiaoli HouGlobal Product Development, Shanghai Henlius Biotech, Inc., Shanghai, P. R. China.
Haoyu YuGlobal Product Development, Shanghai Henlius Biotech, Inc., Shanghai, P. R. China.
Jing LiGlobal Product Development, Shanghai Henlius Biotech, Inc., Shanghai, P. R. China.
Qingyu WangGlobal Product Development, Shanghai Henlius Biotech, Inc., Shanghai, P. R. China.
Jun ZhuGlobal Product Development, Shanghai Henlius Biotech, Inc., Shanghai, P. R. China.
Yuankai ShiDepartment of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.ORCID https://orcid.org/0000-0002-8685-6744
ASTRUM-002 Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedProto-Oncogene MasAntibodies, Monoclonal, HumanizedMAS1 protein, humanProto-Oncogene Mas

Identifiers

PMID42282892
PMCPMC13250280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.